BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250901T181658EDT-1305GLtnP1@132.216.98.100
DTSTAMP:20250901T221658Z
DESCRIPTION:Abstract:\n\nIn our efforts to identify novel small molecule in
 hibitors for the treatment of adrenoleukodystrophy (ALD)\, we conducted a 
 high-throughput radiometric screen for inhibitors of elongation of very lo
 ng chain fatty acid 1 (ELOVL1) enzyme. We developed a series of highly pot
 ent\, central nervous system (CNS)-penetrant pyrimidine ether-based compou
 nds with favorable pharmacokinetics. Key compounds are selective inhibitor
 s of ELOVL1\, reducing C26:0 VLCFA synthesis in ALD patient fibroblasts an
 d lymphocytes in vitro. Several compounds from this series reduced C26:0 l
 ysophosphatidyl choline (LPC)\, a subtype of VLCFA\, in the blood of ATP b
 inding cassette transporter D1 (ABCD1) KO mice\, a murine model of ALD to 
 near wild-type levels. This series of compounds are a low-molecular-weight
 \, potent ELOVL1 inhibitors that may serve as a useful tools for exploring
  therapeutic approaches to the treatment of ALD.\n\n \n\nBio:\n\nMichael J
 . Boyd is a Senior Principal Scientist at Xenon Pharmaceuticals (Boston\, 
 MA). He completed his BSc and MSc at Concordia University under the superv
 ision of Prof. Youla Tsantrizos. He first joined Merck-Frosst (Kirkland\, 
 PQ) in 1999 where he worked on several projects\, including the discoverie
 s of Laropiprant and Odanacatib. He then joined Vertex Pharmaceuticals (Bo
 ston\, MA) as Director of Chemistry\, where he was involved in several key
  projects\, including the discoveries of Pimodivir\, a Phase II antiviral 
 drug for the treatment of influenza\, and VX-864 (a Phase II drug for the 
 treatment of AAT deficiency). He moved to Xenon Pharmaceuticals in 2021.\n
DTSTART:20240206T180000Z
DTEND:20240206T193000Z
LOCATION:OM 10
SUMMARY:Chemical Society Seminar: Michael Boyd- Discovery of Novel\, Orally
  Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1. Part 2: The Dis
 covery of Pimodivir\, a Novel\, First-in-Class\, Orally Bioavailable Azain
 dole Inhibitor of Influenza PB2.
URL:/chemistry/channels/event/chemical-society-seminar
 -michael-boyd-discovery-novel-orally-bioavailable-pyrimidine-ether-based-3
 54053
END:VEVENT
END:VCALENDAR